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Abstract: Background: Solid lipid nanoparticles (SLNs) are attractive drug delivery systems for
lipophilic molecules like curcumin (CURC) with low chemical stability. Methods: A simple,
innovative, and cold-operating method, named “cold dilution of microemulsion” is developed
by the authors to produce SLNs. An oil-in-water microemulsion (µE), whose disperse phase consisted
of a solution of trilaurin in a partially water-miscible solvent, was prepared after mutually saturating
solvent and water. Trilaurin SLNs precipitated following solvent removal upon water dilution of
the µE. After SLN characterization (mean size, Zeta potential, CURC entrapment efficiency, and
over time stability), they were tested for in vitro cytotoxicity studies on pancreatic adenocarcinoma
cell lines and for in vivo preliminary biodistribution studies in Wistar healthy rats. Results: CURC
loaded SLNs (SLN-CURC) had mean diameters around 200 nm, were negatively charged, stable over
time, and able to entrap CURC up to almost 90%, consequently improving its stability. SLN-CURC
inhibited in vitro pancreatic carcinoma cell growth in concentration-dependent manner. Their in vivo
intravenous administration suggested a possible long circulation. Conclusions: These results,
according to a concomitant study on chitosan-coated SLNs, confirm the possibility to apply the
developed SLN-based delivery systems as a means to entrap CURC, to improve both its water
dispersibility and chemical stability, facilitating its application in therapy.
Keywords: poorly water-soluble drug; nanoparticles; microemulsions; cell line; cancer chemoprevention;
drug delivery system
1. Introduction
Curcumin (CURC) is a polyphenolic yellow pigment derived from the rhizome of Curcuma
longa, which has been and is currently subjected to intensive investigations because of its multiple
therapeutic properties.
CURC has several well-documented therapeutic effects [1], including antidiabetic, antihypertensive,
anticancer, anti-inflammatory, and antimicrobial properties. Owing to its multitargeting ability in several
pathological conditions, it has long been considered as a potential therapeutic agent. Moreover, CURC
is described as having a role in reversing multidrug resistance (MDR) through the modulation of Pg-p,
inhibiting its function in several in vitro cell line and in vivo tumor models [2].
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Unfortunately, like many other lipophilic small molecules, CURC’s efficient use in clinical
scenarios is limited by its low hydrophilicity and poor intrinsic dissolution rate, by unfair physical
and chemical stability, low bioavailability due to the pitfalls of poor aqueous solubility [3], poor
pharmacokinetics, rapid metabolism, and low penetration and targeting efficacy.
By conjugating CURC to metal oxide nanoparticles or entrapping it in lipid/polymeric
nanoparticles, liposomes, dendrimers, nanogels, nanoemulsions [4], and polymeric nanoparticles,
its water-solubility and bioavailability can be improved and thus increase its pharmacological
effectiveness [5,6]. Some Authors [7] developed chemically crosslinked hydrogels containing CURC as
hydrophobic drug molecule models and proposed them for prolonged delivery of CURC.
Solid lipid nanoparticles (SLNs) are attracting a number of researchers as an alternative novel drug
delivery system for lipophilic molecules like CURC. As assessed by literature data, SLN entrapment
not only improves CURC bioavailability [8], but also increases its chemical stability [9]. Additionally,
particle size plays an important role in controlling the efficiency of transporting and delivering
therapeutic agents by conventional ways, because small sized-particles are accompanied by high
surface area, which is particularly suitable to modulate drug delivery to the target organ [10].
Moreover, SLNs represent an alternative option to the traditional colloidal drug delivery systems,
such as emulsions, liposomes, and polymeric micro and nanoparticles, because the problems related
to industrial production scale-up, sterilization, and mid-term storage are reduced [11]. SLNs are
composed of a solid lipid matrix often covered with a surfactant or phospholipid layer; indeed, their
main advantage in drug delivery is related to their nanometric size (below 1000 nm) and to the presence
of physiological or biocompatible lipids or lipid molecules, solid at room conditions, with a history of
safe use in therapy. Lipophilic, as well as hydrophilic drugs (thanks to hydrophobic ion pairing or
lipophilic pro-drug preparation), can be loaded in SLNs with high entrapment efficiency.
Over the last 20 years, several methods of SLN production have been thoroughly described in
literature: high-pressure homogenization [12], hot microemulsions [13], solvent-based methods such
as solvent injection [14], solvent diffusion or evaporation from oil in water (O/W) emulsion [15], and
fatty acid coacervation [16].
Most of these techniques require critical process parameters, like high temperatures and/or high
pressures that may cause both thermodynamic and mechanic stress to the resulting SLNs; moreover,
solvents used are neither completely lacking of toxicity, nor physiologically compatible with the
human body. Fatty acid coacervation is a rather simple preparation method, which avoids the use of
solvents and operates at rather mild temperatures; indeed, its application is limited only to the use
of fatty acid as SLN lipid matrix. In addition, the sudden pH variation (from very alkaline to acidic
conditions) can hinder the entrapment of drugs whose stability is negatively influenced by acidic or
alkaline conditions.
In this experimental paper, a new method of SLN preparation called “cold dilution of
microemulsion” [17] is described. It can be considered as an evolution of the "solvent diffusion"
method described in the literature [15]. This production method involves the preparation of an O/W
µE at room temperature, whose hydrophilic and lipophilic phases are mutually saturated, using a
solid lipid dissolved in a partially water soluble organic solvent as oil phase. SLNs precipitate as a
lipid solid matrix following solvent removing upon µE water dilution. Such a method combines the
advantages of the emulsion solvent diffusion technique with the high stability and the super solvent
properties of microemulsion systems. This technique does not require low or high temperatures, other
than the method patented by Gasco [13] which exploited a molten lipid substance added of a hot
aqueous surfactant-cosurfactant dispersion. Moreover, in our method neither pH modification, nor
ultrasonication, nor homogenization, nor pressure variations are required, nor are toxic solvents used
in the view of a future industrial production and therapeutic application.
Finally, the possibility of loading CURC in SLNs prepared by the “cold dilution of microemulsion”
technique is exploited to study in vitro their possible application as anticancer agent on different
pancreatic tumor cell lines, and to preliminary test their biodistribution patterns in laboratory animals.
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2. Materials and Methods
2.1. Chemicals
Trilaurin (TL), tristearin, myristic acid, glyceryl monostearate, ethyl acetate (EA), benzyl alcohol
(BenzOH), triacetin (TA), butyl lactate (BL), polysorbate (20, 40, 80), sodium taurodeoxycholate (Na
TdC), sodium taurocholate (Na TC), sodium glycocholate (Na GC), sodium cholate (Na C), Pluronic®
F68, polyvinyl alcohol (PVA) 9000, PVA 14000, 1,2 propanediol, curcumin and Sepharose® CL 4B were
purchased from Sigma (Dorset, UK). Trimyristin was from Alfa Aesar (Karlsruhe, Germany), glyceryl
dibehenate was from Gattefossé (Weil am Rhein, Germany), Epikuron® 200 (lecithin-phosphatydil
coline 92%) from Cargill (Minneapolis, MN, USA), and Cremophor® RH 60 (PEG-60 hydrogenated
castor oil) from BASF (Ludwigshafen, Germany).
2.2. SLN Preparation
SLNs were prepared by the method named “cold dilution of microemulsion” [17]; briefly, a
preliminary screening on several compositions was performed, operating at room temperature, to
obtain the suitable O/W µE whose disperse phase consisted in a solution of a solid lipid dissolved
in a partially water miscible solvent. The solvent and the external phase, consisting of water, were
mutually saturated at 25 ± 2 ◦C for 2 h in order to ensure the initial thermodynamic equilibrium of
both liquids, before using them in µE formulation. Lipid nanoparticles were precipitated by quickly
adding 5 mL of water into the µE (1 mL) to remove the solvent from the disperse phase and extract it
into the continuous phase.
µEs were obtained with biocompatible GRAS ingredients (Generally Recognized As Safe). Among
different lipids tested (TL, trimyristin, tristearin, myristic acid, glyceryl dibehenate, and glyceryl
monostearate), a TL solution in EA was chosen as oil phase, because of its highest solubility in this
partially water-miscible solvent (Table 1). EA and water were mutually pre-saturated before using
them in µE preparation (EAs and Ws respectively). BenzOH, TA, BL were also tested as partially
water-miscible solvents (water saturated) to solubilize the lipid.
Table 1. Solubility (mg/mL) of trilaurin (TL) in water partially miscible solvents and water solubility
of the solvents (25 ◦C).
Solvent Solubility of TL in Water Saturated Solvent (mg/mL) Solvent Water Solubility (g/100 mL)
TA <300 6.1
BL <300 4.2
EA >300 8.7
BenzOH <300 4.3
Epikuron® 200 was chosen as surfactant together with polysorbate (20, 40, 80) or Cremophor®
RH 60 at 3:1 w/w constant ratio.
Na TdC, Na TC, Na GC, Na C were tested as co-surfactants, BenzOH was chosen as a co-solvent.
A formulation study was performed varying the percentages of surfactant and
co-surfactant/co-solvent. The optimal µE formulation, in the absence of any drug, called
µE1, is reported in Table 2.
µE1 (1 mL) was then diluted with a 2% w/w polymeric aqueous solution (5 mL) to precipitate
SLNs. In order to avoid SLN aggregation [16], different polymers (Cremophor® RH60, Pluronic®
F68, PVA® 9000, PVA® 14000) and different percentages of Pluronic® F68 were tested to check the
best conditions to obtain small and non-aggregated SLNs. Probably, the polymer disposition on SLN
surface influences surface hydrophilicity and charge. A formulation study was then performed to
optimize SLN size.
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Table 2. µE composition. µE1: empty µE; µE2: µE to be loaded with curcumin (CURC).
Components µE1 Composition (w/w %) µE2 Composition (w/w %)
TL 3.33 4.35
EAs 14.97 13.06
Epikuron® 200 12.48 10.88
Cremophor® RH60 4.16 3.63
Ws 58.22 50.80
Bile salt 2.49 2.18
BenzOH 4.35 –
1,2 Propanediol – 15.10
2.3. Pseudo-Ternary Diagrams
Phase diagram was constructed at room temperature. The resultant phase behavior was
mapped on pseudo-ternary phase diagrams, constructed by titrating a series of lipid and
surfactant/co-surfactant mixtures with aqueous phase (Ws/BenzOH mixture at constant 13:1 w/w
ratio). Epikuron® 200-Cremophor® RH60-Na TC (3:1:0.6 w/w/w) was used as surfactant/co-surfactant
mixture, while the lipophilic phase consisted of a TL solution (300 mg/mL) in EAs. Appropriate
amounts of surfactant/co-surfactant and lipophilic phases were weighted (1 g) into glass ampules,
shaken for sufficient time to attain equilibrium, and then progressively enriched with the aqueous
phase, added dropwise. The amounts of aqueous phase at which the transparent/opaque transition
occurred were used to determine the phase domains. The domain of transparent, isotropic systems
with mean diameter >5 nm was considered as the µE phase, while the domain of existence of turbid
systems was classified as the emulsion phase. The domain of liquid crystals was determined by
interposing the system between two polarized lenses and observing the different optical properties of
µE and liquid crystalline systems [18].
For the purposes of this study, a schematic representation was sufficient as a guide to follow
the evolution of phase equilibrium. This experimental procedure was repeated for other points of
surfactant/co-surfactant to lipid weight ratios, and the corresponding phase diagram was constructed.
2.4. CURC Loaded SLNs
With the aim to check the potential applications of µE-derived SLNs in anticancer drug delivery,
CURC was incorporated in the µE whose composition is described in Table 2 (µE2), in which Na
TC was the selected bile salt. To obtain the maximum achievable CURC loading without negatively
affecting the stability of the system, it was necessary to substitute BenzOH with 1,2 propanediol. In
such a way, increasing amounts of drug, up to 11 mg/mL µE, were introduced in the formulation
described in Table 2, in order to obtain the maximum loading in the lipid matrix. µE2 (1 mL) was
diluted with a 2% w/w Pluronic® F68 aqueous solution (5 mL) to precipitate CURC loaded SLNs.
2.5. Gel Filtration of SLNs
CURC loaded SLNs and free CURC were separated by gel filtration. A volume of SLN suspension
(1 mL) was put on the top of the gel filtration (GF) column and the sample was then eluted by gravity,
adding a hypertonic phosphate buffered saline (NaCl and KCl at 2:1 ratio). The stationary phase
was a matrix of cross-linked agarose (Sepharose® CL 4B). Opalescent fractions containing purified
SLNs, whose scattering was monitored by DLS technique (90 Plus-Particle Size Analyzer, Brookhaven
Instruments Corporation, Long Island, NY, USA), were pooled and concentrated under N2 or by
freeze-drying, without adding any cryoprotectant using a Modulyo Freeze Dryer (Edwards Alto Vuoto,
Trezzano sul Naviglio, Italy). When the volume of the N2-flushed suspension was reduced to almost
1 mL, N2 flux was stopped and SLNs were analyzed for particle size, shape, and CURC concentration.
Freeze-dried SLNs were reconstituted in 1 mL water and they were analyzed for particle
size determination.
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Gel filtration should eliminate drug or surfactants/co-surfactants excess adsorbed to SLN surface.
2.6. Particle Size and Zeta Potential Determination
Size distribution, polydispersity index (PI), and Zeta potential measurements were determined
1 h after SLN preparation using DLS technique. Size measurements were obtained at an angle of 90◦ at
25 ◦C. Before the analysis, SLN suspensions were 1:20 diluted with MilliQ water for size determination
or with 0.01 M KCl for Zeta potential determination, in order to achieve the suitable conductivity.
Size measurements were also recorded diluting samples with the grown medium (DMEM) used to
culture cells to mimic the conditions under which SLNs undergo in vitro experiments. All data were
calculated on triplicate samples.
2.7. Differential Scanning Calorimetry (DSC)
DSC studies were performed to investigate CURC-lipid interactions and the crystallinity of both
CURC and lipid, because these parameters might influence the release.
Perkin Elmer differential calorimeter (DSC7, Perkin Elmer, Nortwalk, CT, USA) equipped with
an instrument controller Tac 7/DX (Perkin Elmer) was used. A heating rate of 10 ◦C/min was
employed in the 25–200 ◦C temperature range. SLN suspensions were freeze-dried without adding
any cryoprotectant using a Modulyo Freeze Dryer (Edwards Alto Vuoto, Trezzano sul Naviglio, Italy).
Freeze-dried SLNs were weighted and placed in a conventional aluminum pan for analysis.
The degree of crystallinity of SLNs was estimated by calculating the ratio between the melting
enthalpy/g lipid in SLN dispersion and the melting enthalpy/g of the bulk material [19,20].
2.8. Scanning Electron Microscopy (SEM)
Surface morphology of SLNs was obtained by SEM using Stereoscan 410 (Leica, Wetzlar,
Germany). The nanoparticle suspension was fixed on a metallic stab, evaporated under vacuum
and then coated with gold (SCD 050, Leica, Wetzlar, Germany) under vacuum. The gold-coated
particle layer was scanned using the accelerating voltage scanning of 20 kV.
2.9. In vitro Quantification of CURC
High-performance liquid chromatography (HPLC) analysis was performed using a LC9 pump
(Shimadzu, Tokyo, Japan) with an Inertsil® ODS-2 5 µm 150 × 4.6 mm column and a C-R5A integrator
(Shimadzu, Tokyo, Japan); detector: UV-Vis λ = 450 nm (Shimadzu, Tokyo, Japan).
CURC was eluted in isocratic conditions at a flow rate of 1.0 mL/min using methanol/acetic acid
3.5% (70:30 v/v) as mobile phase. Injection volume was 20 µL, and retention time of CURC was 6 min.
A calibration curve with acceptable linearity (R2 = 0.9998) was constructed by plotting the peak
area versus CURC concentration within 0.2–20 µg/mL concentration range. The relative standard
deviation (RSD) of intra- and inter-day precision at three concentrations (0.2, 2, and 20 µg/mL) was
less than 3%, and the accuracy ranged from 97.0% to 102.5%.
2.10. CURC Concentration in SLN Suspension and Entrapment Efficiency (%EE)
CURC concentration in SLN suspension after gel filtration (GF) was determined by the HPLC
method used for in vitro quantification of CURC. The drug amount resulting after GF of SLNs was
considered as totally entrapped in the SLN matrix. %EE is calculated as the ratio between the amount of
SLN-entrapped drug (post-column drug concentration) and the total amount used in SLN preparation
(pre-column drug concentration) × 100.
2.11. CURC Release from SLNs
In vitro CURC release was determined using the non-equilibrium dialysis method [21]. A
multicompartmental rotating cell system was used; donor and receptor compartments had a volume
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of 1.5 mL each. The experiments were carried out at room temperature. As hydrophilic membrane,
Servapor® dialysis tubing (Serva, Heidelberg, Germany), cut-off 12,000–14,000 Da, was used; the
effective membrane area was 2 cm2.
The receiving medium was 10% v/v PEG 300 aqueous solution. PEG 300 was added to improve
CURC dissolution in an aqueous medium, maintaining sink conditions. A saturated CURC reference
solution in 10% v/v PEG 300 and a CURC-loaded SLN suspension, obtained from µE2 containing
9 mg/mL CURC, and called SLN-CURC, were studied as donor formulations. At fixed times, the
receptor solution was tipped out and the cell was refilled with fresh receiving medium. Drug
concentration in the receptor phase was determined by the HPLC method for in vitro quantification of
CURC. The results were evaluated as CURC apparent permeability constant, Kpapp (cm h−1) calculated
from the slope of the straight section of the curve obtained by plotting the amount of CURC diffused
from the donor formulation versus time, assuming pseudo zero-order kinetics.
2.12. SLN and CURC Stability
SLN mean diameters and CURC concentration in SLN-CURC, stored at 4 ± 1 ◦C, were monitored
for 30 days at fixed time intervals to study SLN physical stability and CURC chemical stability in
SLNs over time. Mean sizes and Zeta potential were determined by DLS, whilst CURC concentration
(µg/mL) in SLN dispersion after GF was determined by HPLC, as described above.
As pure CURC is highly unstable to chemical degradation in alkaline aqueous solutions
(pH ≥ 7.0) [22], CURC chemical stability in SLN-CURC was also evaluated after incubating them in
phosphate buffer solution (PBS) at pH 7.4 for 24 h and comparing it to a saturated solution of CURC in
the same phosphate buffer. For this purpose, native CURC was dissolved in PBS pH = 7.4 with the
help of PEG 300 (final PEG concentration 10% v/v). CURC was added up to saturation (15 µg/mL).
2.13. Empty SLN in vitro Toxicity Studies on Podocytes and HUVEC
In this study, lines of immortalized human podocytes obtained by infection of cultures of renal
cells with a hybrid Adeno5/SV40 virus were used. Primary cultures of human podocytes were
kindly provided by Prof. G. Camussi (Department of Internal Medicine and Center for Molecular
Biotechnology, University of Turin, Turin, Italy).
Podocytes were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Manufacturer, city,
country) supplemented with fetal bovine serum (FBS) 10%, penicillin (100 IU·mL−1), streptomycin
(100 µg·mL−1), and L-glutamine (2 mM).
HUVEC were isolated from human umbilical veins by trypsin treatment (1%) and cultured in
M199 medium with the addition of 20% fetal calf serum (FCS), 100 U/mL penicillin, 100 µg/mL
streptomycin, 5 UI/mL heparin, 12 µg/mL bovine brain extract, and 200 mM glutamine. HUVEC
were grown to confluence in flasks and used at the 2nd–5th passage. The use of HUVEC was approved
by the Ethics Committee of the “Presidio Ospedaliero Martini” of Turin and conducted in accordance
with the Declaration of Helsinki. Written informed consent was obtained from all donors.
The day before the experiment, podocytes and HUVEC were plated on 96-well culture plates
(3 × 103 cells per well). Then, they were treated with empty SLNs (1% w/w TL), progressively diluted,
and after 72 h incubation, the amount of viable cells was evaluated by MTT (Sigma-Aldrich, Milano,
Italy) inner salt reagent at 570 nm, as described by the manufacturer’s protocol. The controls (i.e.,
cells that had received no drug) were normalized to 100%, and the readings from treated cells were
expressed as viability inhibition percentage.
2.14. SLN-CURC in vitro Cytotoxicity Studies
The human tumor cells CFPAC-1 and PANC-1 were obtained from ATCC (Milan, Italy) and used
to perform in vitro cytotoxicity test. CFPAC-1 and PANC-1 cell lines (800/well) were seeded in 96-well
plates and incubated at 37 ◦C, 5% CO2 humidified atmosphere for 24 h in DMEM supplemented with
FBS 10%, penicillin (100 IU·mL−1) /streptomycin (100 µg·mL−1), and L-glutamine (2 mM).
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Then, they were treated with free CURC, SLN-CURC diluted to obtain CURC in the 0.5–10 µM
concentration range, based on CURC incorporation and empty SLNs with the same dilution. After
72 h incubation, the amount of viable cells was evaluated by MTT. The controls (i.e., cells that had
received no drug) were normalized to 100%, and the readings from treated cells were expressed as
viability inhibition percentage.
2.15. Biodistribution of SLNs
Because the bioavailability of orally administered CURC is poor, primarily due to low absorption,
rapid metabolism, and fast elimination, in our study we opted to investigate the parenteral
administration of CURC.
SLN-CURC and CURC solution in normal saline with 10% w/w Tween® 80 (surfactant allowed for
intravenous administration, here used to increase CURC solubility) were administered at 2 mg/kg
dose through a catheter surgically positioned in the jugular vein of male Wistar healthy rats (weight
250 g, age 3 months). Each experiment was performed on 4 rats for each administered sample.
The procedures conformed to the Ethics Committee of University of Turin’s institutional
guidelines on animal welfare (D. Lgs. 26/2014) as well as international Guidelines, and all efforts were
done to minimize the number of animals and their discomfort (3R guidelines). All experiments on
animal models were performed according to an experimental protocol approved by the University
Bioethical Committee, and authorized of Italian Ministry of Health (authorization n. 0165/2015).
At scheduled times (30, 60, and 120 min after administration), rats were sacrificed by CO2-induced
euthanasia; plasma was withdrawn, and organs (liver, spleen, kidneys, lungs, heart, pancreas, and
brain) were removed surgically. Organs were homogenized with UltraTurrax® (IKA, Staufen, Germany)
for 5 min in water at a tissue concentration of 250 mg/mL. Tissue homogenates and plasma were
treated with CH3CN (1:5 v/v) as protein precipitant, vortexed for 60 s and centrifuged at 6000 rpm
for 5 min. The organic phase was collected and analyzed by HPLC method performed through a
YL9100 HPLC system equipped with a YL9110 quaternary pump, a YL9101 vacuum degasser and a
Shimadzu RF-10A fluorescence detector (Shimadzu, Tokyo, Japan), linked to YL-Clarity software for
data analysis (Young Lin, Hogye-dong, Anyang, Korea).
HPLC analysis was performed with LiChrospher® RP18 5 µm 250 × 4.6 mm column, flow
rate = 1 mL/min; A = 3.5% v/v acetic acid in water, B = methanol, gradient (B%, time (min): 40, 10;
90, 5; 40, 1): Rt = 12 min (λex = 409 nm, λem = 535 nm).
2.16. Data Analysis
Data are shown as mean ± S.E.M. Statistical analyses were performed with Prism 3.0 software
(GraphPad Software, La Jolla, CA, USA) using one-way ANOVA and the Dunnett test.
3. Results and Discussion
3.1. SLN Formulation and Characterization
TL dissolved in EAs was chosen as lipid matrix, as EA is the only solvent, among those taken into
account, able to solubilize TL, allowing to obtain a sufficiently concentrated lipid solution.
When 300 mg/mL TL was dissolved in water-saturated solvent (EAs), its resulting percentage in
µE was almost 3%, considering that 200 µL of such solution were used to obtain the µE.
After identifying the quali-quantitative composition of the µE, the pseudo-ternary phase diagram
was constructed (Figure 1). The top apex of the system represents the lipophilic phase (EAs-dissolved
TL) and the remaining two apices represent the surfactant/co-surfactant mixing ratio (lecithin-PEG-6
hydrogenated castor oil-Na TC) and aqueous phase (Ws/BenzOH). The region M on phase diagram
indicates the fluid transparent isotropic µE domain, in which µEs were stable for a sufficiently long
time (at least 1 month) at room temperature (25 ◦C). Birefringent liquid crystalline regions are marked
LC. Unmarked areas indicate multiphase regions.
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Figure 1. Phase diagram at room temperature (25 ◦C) of the systems containing lipophilic
phase/aqueous phase/surfactant:co-surfactant (trilaurin (TL) solution in EAs/Ws-BenzOH/
lecithin-PEG-6 hydrogenated castor oil-sodium taurocholate (Na TC). M: µE domain; LC: liquid
crystal domain.
The construction of the pseudo-ternary diagram was necessary to identify the boundaries between
the areas f the M a d LC existence fields, since only by diluting microemulsion system was it possible
to obtain SLN precipitation. No diff r c betwe n µE with 1,2 propanediol or BenzOH was n ted
about the boundaries f existence field of M and LC.
The formulation without CURC (µE1) with Na TC as bile salt, reported in Table 2, was chosen
to precipitate SLNs in water in the presence of different polymers used as stabilizers. After dilution,
the partially miscible solvent (EAs), present in the oil phase, diffused into the un-saturated aqueous
solution determining t e precipitatio of spherical-shaped TL-SLN, which were in the submicron
size range. It is very difficult to foresee if SLN mean dia eters will keep the size of oil nanodroplets
originally present in the µE. Indeed, even if µE droplets are generally c mprised in 10–150 nm, it is
very hard to measure them directly in the µE by DLS or by microscopy without perturbing (by diluting
or pretreating) the equilibria of a liquid system. Moreover, it might be that SLN mean diameters are
higher than those of µE droplets, as in the precipitation step, as certain droplet aggregation ca occur.
The selected SLNs, consisting of a TL core, were stabilized with different polymer solutions.
Formulation studies were carried out screening differe t polymers to select the one allowing the
formation of stable SLN suspension, avoi ing nanoparticle aggregation. In Table 3, mean diameter and
PI of empty SLNs, obtained from µE1 after precipitation of the lipid matrix in 2% w/w aqueous solution
of different polymers, are reported. The smallest SLN diameter was obtained using Pluronic® F68
as stabilizer. Pluronic® F68, unlike PVAs and Cremophor® RH60, is an amphiphilic polymer, whose
lipophilic probably strongly interacts with the lipophilic surface of SLNs.
Table 3. Mean diameter (nm) ± standard error (PI) of empty solid lipid nanoparticles (SLNs) dispersed
in different 2% w/w polymer solutions.
Samples Mean Diameter (nm)± S.E. (PI)
SLNs in PVA® 9000 200.2 ± 2.2 (0.191)
SLNs in Cremophor® RH60 223.9 ± 2.4 (0.224)
SLNs in Pluronic® F68 151.9 ± 3.4 (0.210)
SLNs in PVA® 14000 282.2 ± 11.5 (0.139)
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A percentage of Pluronic® F68 ranging from 2 to 3% w/w produced SLNs with the smallest
diameters (Figure 2). Probably, a percentage of 1% w/w was insufficient to stabilize SLN surface,
whereas 4% w/w might adsorb onto SLN surface to a greater extent, determining a sharp increase in
mean diameters. Then 2% w/w Pluronic® F68 aqueous solution was chosen to dilute the subsequent
microemulsion formulations.
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Figure 2. Mean diameter (nm) of empty solid lipid nanoparticles (SLNs) dispersed in Pluronic® F68
aqueous solution at different polymer percentages.
A further modification of µE formulation was performed screening different bile salts in order to
select the best performing one regarding SLN mean diameters and PI. Indeed, bile salts are naturally
occurring substances whose amphipathic, detergent-like characteristics determine a wide range of
biological activity; the ability to form micellar aggregates both in pure and in mixed form with
Epikuron® 200 was already exploited by employing them as co-surfactants in lecithin-stabilized
µE [23].
Several SLNs were obtained using Na TC, Na TdC, Na GC or Na C as co-surfactant, whose mean
diameters are reported in Table 4: among the different bile salts screened, Na TC allowed to obtain
SLN with the smallest size (152 nm). Perhaps the deoxidation at the 7 position of Na TdC is responsible
for its higher rigidity and hydrophobicity than Na TC, which can hinder the interaction with the lipid
matrix; moreover, in the cholate series, the presence of taurine confers suitable amphiphatic properties
to the bile salt.
Table 4. Mean diameter (nm) ± standard error and pH of empty SLN suspensions in Pluronic® F68,
prepared screening different bile salts in µE formulation.
SLN Mean Diameter (nm)± S.E. pH of SLN Suspension
SLNs with Na TdC 332 ± 1.4 4.43
SLNs with Na TC 152 ± 2.4 3.89
SLNs with Na GC 334 ± 1.5 4.57
SLNs with Na C 230 ± 1.7 6.49
For this reason, Na TC-containing µE1 was selected for further experiments.
When CURC was added to µE1, some adjustments were needed in its formulation to maintain
transparency and stability, which are necessary conditions of µEs: BenzOH was replaced by 1,2
propanediol up to 15.10% w/w, obtaining µE2, in which it was possible to load increasing amounts of
CURC (up to 11 mg/mL).
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Both empty and CURC-loaded SLNs, obtained by diluting µE in aqueous Pluronic® F68 solution,
were purified by GF technique.
CURC loaded SLN size slightly increased upon increasing amounts of loaded CURC, compared
to their respective empty SLNs; this is probably due to the presence of CURC inside of the lipid core;
however, mean diameters of SLNs formed from µE2 did not markedly exceed 200 nm (Table 5). All
formulations were negatively-charged: Zeta potential varied from −10 to −19 mV upon increasing
amount of loaded CURC, indicating a relatively fair stability and dispersion of the systems. Generally,
the presence of both Epikuron® 200 and Na TC in SLN formulations determines a marked negative
charge onto nanoparticle surface; in this case, the slightly negative value of Zeta potential was
attributed to the presence of Pluronic® F68, a non-ionic surfactant used in the production of relatively
stable dispersions. As it is non-ionic, the surfactant can shield the electric double layer. Pluronic® F68
can also provide additional steric stabilization of particles [24,25].
Table 5. Mean diameter (nm) ± standard error (PI), Zeta potential (mV), and entrapment efficiency
(%EE) ± standard error of SLNs with increasing amount of CURC, after purification by gel filtration
(GF) technique and concentration under N2.
mg of CURC Added Mean Diameter (nm)± S.E. (PI) Zeta Potential (mV)± S.E. %EE± S.E.
3 mg in SLN 206.2 ± 4.4 (0.220) −9. 89 ± 1.98 87 ± 1.1
5 mg in SLN 169.8 ± 4.7 (0.255) −10.02 ± 2.66 78 ± 1.3
7 mg in SLN 185.9 ± 2.9 (0.265) −10.20 ± 2.10 74 ± 1.8
9 mg in SLN 203.5 ± 5.9 (0.259) −10.06 ± 2.66 75 ± 1.0
11 mg in SLN 215.3 ± 5.4 (0.222) −18.96 ± 2.88 70 ± 2.1
CURC %EE slightly decreased, whilst, CURC loading in SLNs increased as a function of increasing
amounts of CURC in µE up to 9 mg CURC; no further increase in CURC loading was noted for higher
CURC amounts. A mass of 9 mg CURC corresponded to a 112.5 µg CURC/mg lipid loading, which
can be considered as the saturation concentration of CURC in SLN lipid matrix.
SLNs obtained from µE2 containing 9 mg/mL CURC, called SLN-CURC, were used for
further experiments.
The satisfactory CURC amounts recovered in SLN dispersion indicate the efficiency of the new
preparation method of SLNs from µE, avoiding significant CURC losses during formulation.
After GF, SLNs had to be reconstituted to the initial volume by freeze-drying followed by further
water addition up to the initial volume, or by direct concentration to the initial volume under N2
flux. The concentration under N2 flux did not determine any remarkable mean diameter increase,
meanwhile after freeze-drying some SLN aggregation occurred (Table 6). Growth media do not seem
to influence SLN dimensions, as all formulations maintained their size (± 5%).
Table 6. Mean diameter ± standard error (PI) of empty nanoparticles suspensions in Pluronic® F68
with sodium taurocholate (Na TC) as bile salt (SLN) and SLNs loaded with 9 mg CURC (SLN-CURC),
before and after elution in GF and concentration with two different methods: concentration under N2
or freeze-drying.
Mean Diameter (nm)± S.E. (PI)
Before Elution in GF
Mean Diameter (nm)± S.E. (PI)
After Elution in GF and
Concentration under N2
Mean Diameter (nm)± S.E. (PI)
After Elution in GF and
Concentration Freeze-Drying
SLN 152 ± 2.4 (0.21) 193 ± 0.6 (0.134) 302 ± 2.1 (0.198)
SLN-CURC 204 ± 5.9 (0.26) 173 ± 1.1 (0.123) 468 ± 1.9 (0.188)
The surface morphologies of SLNs were studied using SEM, which confirmed the shape of SLNs,
which were well-dispersed and separated from each other, and looked to be single unities, suggesting
the lack of aggregates (Figure 3).
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500 nm).
To meet the requirement of using SLNs as drug-carrier systems, their solid state after µE dilution
had to be verified. The status of lipid particles was investigated using differential scanning calorimetry
(DSC); moreover, DSC analysis was also aimed to investigate the degree of lipid crystallinity in SLNs
and the eventual presence of polymorphs, as these parameters are strongly correlated with drug
incorporation and release profiles [20].
DSC thermogram of TL (Figure S1), a monoacid triglyceride containing a 12C-chain for each fatty
acid esterified with the glycerol molecule, exhibits a sharp endotherm peak, with onset at 49 ◦C, which
indicates the melting of the stable β-form of TL [26].
The thermogram of SLN-CURC sh ed endotherm peak with onset at 34 ◦C,
proba ly due to the m lting of the unstable β′-form, and no supercooled melt was reveal d. As further
hypo sis, accord ng to Siekmann and Westesen [19], the mel ing point decrease of SLN systems
might be due to th colloidal nature of the particles, in particular to their high surface-to-volume ratio
and not the recrystallization of the lipid matrices in a metastable polymorph. DSC analysis of CURC
showed the melting point at 173.17 ◦C. Moreover, it is interesting to note that it was not possible to
observe the transition peak of CURC in SLN thermograms, confirming CURC entrapment in SLNs.
CURC melting peak was not recorded in the SLN formulation, in accordance with the location of
the drug within the solid lipid matrix.
A degree of crystallinity higher than 30% was obtained for SLNs: when crystallinity decreased
from 100%, a less ordered modification of the lipid matrix is present in SLNs, which might promote
drug release [27].
Over-time stability of CURC in SLN-CURC was studied during 30 day-storage. Physical stability
was checked by monitoring particle mean size and Zeta potential over time by DLS measurements. No
significant modification was noted, either in particle size or in Zeta potential (Figure 4). Furthermore,
polydispersity index was stable over time (data not shown).
Also, CURC concentration in SLN suspensions decreases by approximately 3% during
30 day-storage remaining quite unmodified: this result is actually significant, as CURC entrapment in
SLNs allowed, if not to hinder, at least to slow down CURC degradation.
Indeed, CURC is a hydrophobic polyphenol compound that is unstable in aqueous solution: in a
recent study, Kharat and al. [22] demonstrated the chemical instability of CURC in aqueous solutions
at pH ≥ 7.0 and the tendency to crystallize out of aqueous solutions at pH < 7, the latter phenomenon
being particularly relevant at low temperatures.
To confirm whether our formulation can enhance CURC stability in aqueous media, we incubated
SLN-CURC in PBS (0.1 M, pH 7.4) for 24 h. Monitoring CURC concentration in SLN dispersion
over time, it resulted to be stable, as almost 94% of the initial amount (1042 µg/mL) was found in
SLN dispersion after 24-h incubation, compared with free CURC that in PBS degraded quickly, with
only 50% of the initial amount remaining. These results confirmed the role of the developed lipid
nanoparticulate system to entrap and to protect CURC from aqueous degradation.
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Figure 4. ility of SLN-CURC in term of me n diameter (nm) and CURC c centration
(µg/mL) over time fter storage t 4 ◦C. Zeta potential (mV) was 1 day = −10.02 mV ± 2.32;
6 days = −13.57 mV ± 2.71; 15 days = −18.86 mV ± 2.98; 30 days = −19.53 mV ± 2.77.
In in vitro release expe ime ts, CURC was relea e more slowly from SLNs (Kpapp = 0.015 cm h−1)
than from refere ce CURC solution (Kpapp = 0.075 cm h−1).
A 1-hour lag time was noted for SLN-CURC, which might be due to the drug adsorbed on the
nanoparticles surface (Figure 5). Subsequently, after 6 h the percentage of CURC released was only 12%,
indicating a slow release of CURC from the lipid solid matrices, due to the erosion and degradation of
the components of nanoparticles [28,29]. After 24 h, the CURC amount released from SLN was 20%
compared to 65% from the reference solution.Nanomaterials 2019, 9, x FOR PEER REVIEW 13 of 18 
 
 454 
Figure 5. CURC release from SLN-CURC compared to reference solution (up to 6 h). 455 
3.2. In vitro Cytotoxicity Test 456 
Since SLNs should not be toxic for healthy cells, empty SLN biocompatibility on HUVEC was 457 
verified. Cells were treated with increasing dilutions of empty SLN suspension (1% w/w of TL) for 72 458 
h. After exposure, cell viability was evaluated assessing the number of viable cells by MTT assay, 459 
revealing a cell survival rate higher than 80% for all the dilutions tested (1/100, 1/200, 1/500, 1/1000). 460 
Then we compared the ability of free CURC, empty SLNs, and SLN-CURC to inhibit the growth 461 
of CFPAC-1 and PANC-1 cell lines. Cells were cultured in the absence and in the presence of titrated 462 
amounts of CURC (0.5–10 µM) for 72 h and the amount of viable cells was then assessed by MTT 463 
assay. Figure 6 shows that SLN-CURC inhibited the growth of both cell lines. The effect was 464 
concentration-dependent with small differences between the two cell lines. Probably, PANC-1 cells 465 
internalize CURC better than CFPAC-1 cells, as is reported in all the tested doses; CURC uptake by 466 
PANC-1 cell line is well documented in the literature [30]. 467 
A significant increase of inhibition effect was observed at each CURC concentration on cells 468 
treated with SLN-CURC with respect to the free compound, while empty SLNs did not display any 469 
cytotoxicity. It is noteworthy that, when CURC was loaded in SLNs, an almost 10% cell growth 470 
inhibition resulted for a 0.5 µM CURC, a concentration at which free CURC was ineffective. Studies 471 
reported that drugs exhibited better cytotoxicity profile when incorporated in SLNs compared to free 472 
drug because they have high surface areas for more efficient uptake by cells [31]. These results 473 
revealed the effectiveness of SLNs to release the intact molecule inside the targeted cells. The 474 
mechanism of internalization of SLNs is thoroughly described in literature as occurring through a 475 
receptor-mediated endocytosis through clathrin-coated pits [32]. 476 
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
0 1 2 3 4 5 6
CU
RC
 re
le
as
e 
pe
rc
en
ta
ge
 (%
)
time (h)
reference solution
SLN-CURC
Figure 5. CURC release from SL - c r to reference solution (up to 6 h).
Nanomaterials 2019, 9, 230 13 of 17
At room temperature SLNs are in solid state, as confirmed by DSC analysis. Therefore, the
mobility of incorporated drugs is reduced, which is a prerequisite for controlled drug release.
3.2. In vitro Cytotoxicity Test
Since SLNs should not be toxic for healthy cells, empty SLN biocompatibility on HUVEC was
verified. Cells were treated with increasing dilutions of empty SLN suspension (1% w/w of TL) for
72 h. After exposure, cell viability was evaluated assessing the number of viable cells by MTT assay,
revealing a cell survival rate higher than 80% for all the dilutions tested (1/100, 1/200, 1/500, 1/1000).
Then we compared the ability of free CURC, empty SLNs, and SLN-CURC to inhibit the growth
of CFPAC-1 and PANC-1 cell lines. Cells were cultured in the absence and in the presence of titrated
amounts of CURC (0.5–10 µM) for 72 h and the amount of viable cells was then assessed by MTT
assay. Figure 6 shows that SLN-CURC inhibited the growth of both cell lines. The effect was
concentration-dependent with small differences between the two cell lines. Probably, PANC-1 cells
internalize CURC better than CFPAC-1 cells, as is reported in all the tested doses; CURC uptake by
PANC-1 cell line is well documented in the literature [30].
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Figure 6. Inhibition of proliferation following empty SLN, SLN-CURC, and free CURC administration.
PANC-1 and CFPAC-1 cells (800 cells/well) were treated with increasing concentrations of SLN-CURC
and CURC for 72 h; the result was expressed as the percentage of viable cells versus the control
expressed as mean ± S.E.M (n = 5). Asterisks mean statistically significant differences of SLN-CURC
vs. CURC-treated cells at the same concentrations (* p < 0.05 and ** p < 0.01).
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A significant increase of inhibition effect was observed at each CURC concentration on cells
treated with SLN-CURC with respect to the free compound, while empty SLNs did not display any
cytotoxicity. It is noteworthy that, when CURC was loaded in SLNs, an almost 10% cell growth
inhibition resulted for a 0.5 µM CURC, a concentration at which free CURC was ineffective. Studies
reported that drugs exhibited better cytotoxicity profile when incorporated in SLNs compared to free
drug because they have high surface areas for more efficient uptake by cells [31]. These results revealed
the effectiveness of SLNs to release the intact molecule inside the targeted cells. The mechanism of
internalization of SLNs is thoroughly described in literature as occurring through a receptor-mediated
endocytosis through clathrin-coated pits [32].
3.3. Biodistribution Studies
Before biodistribution experiments, it was mandatory to inject empty SLNs (1% w/w of TL) in rats
to test their biocompatibility: actually, after carefully monitoring rats, neither changes in their behavior,
nor alteration in vital signs were noted in rats up to 48 h after empty SLN intravenous administration
(nanoparticle mean diameter 193 nm).
Moreover, Tween® 80, which was used to improve CURC aqueous solubility, has been widely
used as a solvent for pharmacological experiments [33].
The small number of animals involved in these preliminary investigations hinders one from
drawing precise conclusions about quantitative all-body distribution, but the recovered data can give
us some general information about CURC tracking after intravenous administration of SLN-CURC,
which is summarized as follows.
The preliminary results of biodistribution experiments show that CURC can be delivered by SLN
(with mean diameter 173 nm) to the different organs at concentration comparable with those obtained
by administering CURC in 10% Tween® 80 aqueous solution.
In Figure 7, CURC concentration in each organ is reported for different post-administration
times. When free CURC was administered in 10% w/w Tween® 80 aqueous solution, a maximum
accumulation in liver, lung, and spleen was provided at earlier stages than for SLN, and a progressive
decrease of its concentration over time was noted, in almost all the considered organs. On the contrary,
at 60 min post administration, SLN-CURC revealed the highest concentration/vs. time in almost all
organs and especially in lung, liver, brain, spleen, and pancreas, suggesting a possible long circulation.
These results might be related to the delayed release and the stability increase of SLN-loaded CURC
assessed in in vitro release studies.
As it can be predicted, 60 and 120 min after administration marked CURC accumulation in RES
organs (spleen or liver) was noted when it was loaded in SLNs compared with free CURC solution.
Probably, the small amount of Pluronic® F68 adsorbed onto SLN surface was not sufficient to confer
them stealth properties. Indeed, the higher CURC amount found in pancreas at time, when it was
administered in SLNs, rather than in 10% w/w Tween® 80 aqueous solution, was quite surprising and
worthy of further investigation.
CURC was considered a potential drug to both inhibit cancer and overcome drug resistance [9].
Recently, chemoprevention has emerged as an effective tool in the fight against various types
of cancers, including pancreatic cancer. Of the various chemopreventive agents being studied,
CURC has been proven to be effective in chemoprevention of this cancer. Nevertheless, the clinical
translation of this agent has been significantly hampered due to its poor oral bioavailability after
administration [34]. Engineering a SLN drug delivery system for CURC offers a means of increasing
the bioavailability in the plasma and tissues in comparison to the free form, thereby ultimately
improving the therapeutic efficacy.
Considering the successful results obtained in in vitro cytotoxicity tests on PANC-1 and CFPAC-1
cultures, the in vivo results might be a fair short point to further investigation also concerning in vivo
pancreas tumor models.
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The above mentioned results, although far from being optimal for an in vivo administration, are
encouraging and give us many suggestions about the way to modify SLN composition and surface
properties both to minimize opsonization and to prolong circulation time.
4. Conclusions
In conclusion, five end points have been successfully reached:
• the development of a n w, solvent free, cold-operating, and simple-to-realize tech ique, to obtain
physiologically compatible SLN;
• the feasibility of the µE dilution method for CURC loading;
• the in vitro efficacy of SLN-CURC on two different pancreatic tumor cell lines;
• the lack of adverse effects of SLNs on rats after intravenous administration
• different biodistribution patterns of CURC when in vivo administered in SLNs and prolonged
circulation time when compared with aqueous solution.
These results confirm the possibility to apply the developed SLN-based delivery systems as a
mean both to entrap CURC and to improve CURC water dispersibility and chemical stability, which
would facilitate its application in therapy.
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